- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AGNPF
Recent news which mentions AGNPF
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
From Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
From Benzinga
DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study
August 08, 2023
Tickers
AGNPF
From Benzinga
DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
June 05, 2023
Tickers
AGNPF
From Benzinga
From Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
March 07, 2023
From Benzinga
Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program
March 01, 2023
From Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
February 27, 2023
From Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
From Benzinga
Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program
February 21, 2023
From Benzinga
Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
February 16, 2023
Tickers
AGNPF
From Benzinga
From Benzinga
Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
January 03, 2023
Tickers
AGNPF
From Benzinga
From Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
November 21, 2022
From Benzinga
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
November 16, 2022
Tickers
AGNPF
From Benzinga
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
October 24, 2022
Tickers
AGNPF
From Benzinga
A Foundational Study On Stroke Is Ready. Here Is Why It's Important
September 12, 2022
From Benzinga
Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
September 08, 2022
Tickers
AGNPF
From Benzinga
Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
August 23, 2022
Tickers
AGNPF
From Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
From Benzinga
From Benzinga
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
September 13, 2021
From Benzinga
Investors Should Avoid High-Risk Atossa Therapeutics
August 02, 2021
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.